Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Clinical trial NCT04703686 · COMPLETED

Trial details

NCT number: NCT04703686
Sponsor: The Lymphoma Academic Research Organisation
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma Refractory Refractory Indolent Adult Non-Hodgkin Lymphoma Refractory Transformed B-cell Non-Hodgkin Lymphoma Refractory Primary Mediastinal Large B-Cell Cell Lymphoma Refractory Mantle Cell Lymphoma

Start date: 2021-03-30
Primary completion: 2023-01-10
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.